Decoding Neurological Disease. Building Medicines.

CELLTIUM is developing precision therapies for CMT1A and related neurological disorders. By combining deep disease biology with the proprietary PRECISION™ platform, we are advancing a translationally driven approach to drug discovery.

A New Model for Neurotherapeutics
Through the PRECISION™ platform, we integrate disease biology, quantitative phenotyping, and AI into a single translational framework — from target identification to lead optimization — to build first‑in‑class therapies for underserved neurological diseases.

Targeting the Core Biology
We are advancing a portfolio of mechanistically distinct therapies for CMT1A, including small molecules and targeted biologic approaches, designed to address underlying disease biology, restore peripheral nerve function, and deliver disease-modifying potential.

Partner With Us
We welcome strategic collaborations with pharmaceutical companies, research institutions, and investors across co-development, licensing, and strategic investment — to advance our CMT1A programs and further develop the PRECISION™ platform.

Interested in Our CMT1A Program?

MEET US AT

June 22–25 | San Diego

April 28–30 | Seoul

Targeting the Core Biology We are advancing a portfolio of mechanistically distinct therapies for CMT1A, including small molecules and targeted biologic approaches, designed to address underlying disease biology, restore peripheral nerve function, and deliver disease-modifying potential.

Interested in Our CMT1A Program?

Targeting the Core Biology
We are advancing a portfolio of mechanistically distinct therapies for CMT1A, including small molecules and targeted biologic approaches, designed to address underlying disease biology, restore peripheral nerve function, and deliver disease-modifying potential.